12 results about "Marker vaccine" patented technology

The invention discloses a gene VII type Newcastle disease attenuated marker vaccine strain rMG7-HN-G256E, the preservation number of the gene VII type Newcastle disease attenuated marker vaccine strain is CGMCC (China General Microbiological Culture Collection Center) No.46292, and the whole-genome nucleotide sequence of the vaccine strain is as shown in SEQ ID No: 1; wherein the 256th amino acid glycine (G) of the HN protein is replaced by glutamic acid (E). A Newcastle disease virus reverse genetic manipulation platform is utilized, different sites are mutated on the basis of a Newcastle disease virus MG7 strain, a gene VII type Newcastle disease virus marker vaccine attenuated strain rMG7-HN-G256E which is low in pathogenicity, good in growth characteristic, high in virus titer, stable in passage and excellent in immunogenicity is rescued, and the marker vaccine strain is good in immunogenicity, high in immunogenicity, high in immunogenicity, high in specificity, high in specificity and high in specificity. The vaccine can induce a high-level protective antibody, completely protects immunized chickens, can be used for preventing and controlling the current epidemic gene VII type Newcastle disease virus, and lays a foundation for identifying vaccine immunity and wild virus infection.

The present invention discloses a genetically attenuated marker vaccine strain rMG7-L-V1291I of Newcastle disease virus genotype VII, with a preservation number of CGMCC No. 46291. The complete gene nucleotide sequence of this vaccine strain is shown as SEQ ID No: 1; among them, the 1291st amino acid valine (V) of the L protein is replaced by isoleucine (I). The present invention utilizes a reverse genetics operation platform for Newcastle disease virus, based on the Newcastle disease virus MG7 strain, mutates different sites, and rescues a genetically attenuated marker vaccine strain rMG7-L-V1291I of Newcastle disease virus genotype VII with low pathogenicity, good growth characteristics, high virus titer, stable passage ability, and excellent immunogenicity. This marker vaccine strain has good immunogenicity, can induce high levels of protective antibodies, achieve complete protection for immunized chickens, can be used for the prevention and control of currently prevalent Newcastle disease virus genotype VII, and lay a foundation for differentiating vaccine immunization and wild virus infection.

The present disclosure provides an N protein epitope mutation marker for preparing an epitope deletion-marked vaccine strain of type II porcine reproductive and respiratory syndrome virus (PRRSV) and use thereof, belonging to the technical field of biological products. In the mutation marker, one or more amino acids are mutated based on an epitope sequence at positions 92 to 103 of a C-terminal of an N protein of the type II PRRSV; and the epitope mutation marker has an amino acid sequence shown in SEQ ID NO: 1, where X1 is selected from the group consisting of T, P, and A; and X2 is selected from the group consisting of V and A.

The invention discloses a dual TaqMan real-time fluorescent quantitative PCR (Polymerase Chain Reaction) detection method for zonal Brucella wild strain infection and an A19 delta bpe275 labeled vaccine strain. The dual TaqMan real-time fluorescent quantitative PCR detection method comprises the following steps: extracting nucleic acid of a sample to be detected; the extracted nucleic acid is taken as a template, fluorescent quantitative PCR amplification is simultaneously carried out in the same reaction system, and the reaction system comprises a first primer probe combination for detecting the bpe275 gene, collecting fluorescent signals of the first fluorescent reporter group and the second fluorescent reporter group, and interpreting the detection result according to the amplification condition of the fluorescent signals. According to the present invention, the non-specific amplification risk is significantly reduced by using the specific primer and probe combination aiming at the bpe275 and bab11216 genes, the accuracy and the reliability of the detection result are ensured, the dual-target detection can be completed in the one-time reaction by using the dual-fluorescence real-time quantitative PCR technology, the detection efficiency is significantly improved, and the kit is suitable for the large-batch sample detection.

The invention discloses a gene VII type Newcastle disease attenuated marker vaccine strain rMG7-F-N471A, the preservation number of which is CGMCC (China General Microbiological Culture Collection Center) No.46293. The whole-genome nucleotide sequence of the vaccine strain is as shown in SEQ ID No: 1; wherein the 471st amino acid asparagine (N) of the F protein is replaced with alanine (A). A Newcastle disease virus reverse genetic manipulation platform is utilized, different sites are mutated on the basis of a Newcastle disease virus MG7 strain, a gene VII type Newcastle disease virus marker vaccine attenuated strain rMG7-F-N471A which is low in pathogenicity, good in growth characteristic, high in virus titer, stable in passage and excellent in immunogenicity is rescued, and the marker vaccine strain is good in immunogenicity, high in immunogenicity, high in immunogenicity, high in specificity, high in specificity, high in specificity and high in specificity. The vaccine can induce a high-level protective antibody, completely protects immunized chickens, can be used for preventing and controlling the current epidemic gene VII type Newcastle disease virus, and lays a foundation for identifying vaccine immunity and wild virus infection.

The present application discloses a chimeric classical swine fever virus, a classical swine fever marker vaccine, and a preparation method and application thereof. In the embodiment of the present application, the non-coding region and the main antigenic region of the E2 protein of the attenuated live classical swine fever vaccine strain C were replaced with the corresponding region of the BVDV Hubei strain by reverse genetic manipulation technology, and an infectious clone of the chimeric classical swine fever virus was constructed. The infectious clone was rescued by cell transfection and passage to obtain a chimeric classical swine fever virus with stable characteristics. The chimeric classical swine fever virus can stably replicate in pig-derived cells and has genetic stability and safety; it can induce the production of specific antibodies after immunization of the body, and can also provide the pig with complete protection against lethal infection by the virulent classical swine fever virus. In addition, the strain can immunize to produce BVDV E2-specific antibodies to distinguish between vaccinated pigs and wild-type classical swine fever virus-infected pigs, so that the strain has an application prospect as a classical swine fever marker vaccine.

The invention discloses a gene VII type Newcastle disease attenuated marker vaccine strain rMG7-L-V1291I, the preservation number of the gene VII type Newcastle disease attenuated marker vaccine strain rMG7-L-V1291I is CGMCC (China General Microbiological Culture Collection Center) No.46291, and the whole-genome nucleotide sequence of the vaccine strain is as shown in SEQ ID No: 1; wherein the 1291th amino acid valine (V) of the L protein is replaced by isoleucine (I). A Newcastle disease virus reverse genetic manipulation platform is utilized, different sites are mutated on the basis of a Newcastle disease virus MG7 strain, a gene VII type Newcastle disease virus marker vaccine attenuated strain rMG7-L-V1291I which is low in pathogenicity, good in growth characteristic, high in virus titer, stable in passage and excellent in immunogenicity is rescued, and the marker vaccine strain is good in immunogenicity, high in immunogenicity, high in specificity, high in immunogenicity and capable of being used as a marker vaccine for the Newcastle disease virus. The vaccine can induce a high-level protective antibody, completely protects immunized chickens, can be used for preventing and controlling the current epidemic gene VII type Newcastle disease virus, and lays a foundation for identifying vaccine immunity and wild virus infection.

The present invention relates to immunogen carriers, wherein said immunogen carriers are preferably virus-like particles (VLPs) comprising a plurality of modified PCV2 ORF2 proteins. In particular, the present invention belongs to the field of compliance markers and marker vaccines allowing to distinguish between infected and vaccinated individuals. In particular, it relates to compliance markers for vaccines comprising subunit antigens and DIVA (distinguishing infected from vaccinated animals) systems, which enable to distinguish between animals infected with a pathogen and animals treated with subunit antigens derived from said pathogen.

The application belongs to the technical field of biology and relates to a broad-spectrum monoclonal antibody for recognizing a linear antigen epitope at the C-terminal of foot-and-mouth disease virus VP2 protein and application thereof. The monoclonal antibody pOTB-1 is successfully constructed, the amino acid sequence of the heavy chain variable region is as shown in SEQ ID No. 6, and the amino acid sequence of the light chain variable region is as shown in SEQ ID No. 7. The biological activity of the antibody is verified by indirect immunofluorescence test, enzyme-linked immunosorbent assay and Western-blot. The antibody exhibits broad-spectrum reactivity to O type and A type FMDV and has strong binding affinity. The antibody recognizes a continuous linear B cell epitope at the C-terminal of the structural protein VP2. The epitope sequence is highly conserved among FMDV O type, A type and Asia1 type, which indicates that there is an inter-type common antigen site in the capsid protein VP2. A competitive ELISA detection method is established based on biotinylated pOTB-1, which provides a tool for the prevention and control of FMDV and serological detection, and lays a foundation for the design of FMDV marker vaccine and the evaluation of immunization effect.

The present invention discloses a genotype VII Newcastle disease attenuated marker vaccine strain rMG7-F-N471A, which has a deposit number of CGMCC No.46293. The full gene nucleotide sequence of the vaccine strain is shown in SEQ ID No: 1; wherein, the 471st amino acid asparagine (N) of the F protein is replaced by alanine (A). The present invention utilizes a Newcastle disease virus reverse genetic operation platform, and on the basis of the Newcastle disease virus MG7 strain, mutates different sites to rescue a genotype VII Newcastle disease virus marker vaccine attenuated strain rMG7-F-N471A with low pathogenicity, good growth characteristics, high virus titer, stable passage, and excellent immunogenicity. The marker vaccine strain has good immunogenicity, can induce a high level of protective antibodies, and achieves complete protection for immunized chickens. It can be used to prevent and control the currently prevalent genotype VII Newcastle disease virus and lay the foundation for distinguishing vaccine immunity from wild virus infection.

The invention discloses a classical swine fever virus E2 protein labeled subunit vaccine and a serological differential diagnosis kit matched with the classical swine fever virus E2 protein labeled subunit vaccine. The invention belongs to the field of medical preparations, and relates to a classical swine fever virus E2 protein labeled subunit vaccine and a serological differential diagnosis kit matched with the classical swine fever virus E2 protein labeled subunit vaccine. Wherein the hog cholera virus recombinant E2 protein is obtained by mutating the epitope of the E2 protein of a hog cholera virus vaccine strain LPC, and the amino acid sequence of the mutant protein is SEQ ID No: 1 or a fusion protein obtained by connecting a protein tag to the N terminal or / and C terminal of the SEQ ID No: 1. The E2 marked subunit vaccine prepared by using the recombinant E2 protein has good immunogenicity, the diagnostic kit is prepared by using the E2 protein of the classical swine fever virus vaccine strain LPC and the monoclonal antibody of the DIDA55 recognition epitope of the classical swine fever virus E2 protein, and serological identification of vaccination of pigs without the marked vaccine or wild virus infection is realized, so that purification of classical swine fever is promoted.

This invention discloses a Newcastle disease virus (NDV) genotype VII attenuated marker vaccine strain, rMG7-HN-G256E, with accession number CGMCC No. 46292. The complete nucleotide sequence of this vaccine strain is shown in SEQ ID No: 1; wherein, the 256th amino acid (G) of the HN protein is replaced with glutamic acid (E). This invention utilizes a Newcastle disease virus reverse genetics platform to mutate different sites on the MG7 Newcastle disease virus strain, rescuing a genotype VII Newcastle disease virus marker vaccine strain, rMG7-HN-G256E, which exhibits low pathogenicity, good growth characteristics, high viral titer, stable passage, and excellent immunogenicity. This marker vaccine strain has good immunogenicity, can induce high levels of protective antibodies, and provides complete protection for immunized chickens. It can be used to control the currently prevalent genotype VII Newcastle disease virus and lays the foundation for differentiating between vaccine immunization and wild-type virus infection.